The sale of the Dialysis and BioSentry products to Merit Medical Systems for $100 million is a significant deal for AngioDynamics, which is likely to have a positive impact on its stock price. Additionally, the announcement of preliminary FY23 net sales guidance provides investors with a clearer outlook on the company's future performance, further supporting the stock's upward movement.